Physician profile
Robert J Holmes
NPI 1245210723
$1,250.23
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $199 · 2021: $257 · 2022: $245.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $458.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $217.67 | 2019-2022 | |
| Atricure, INC. | $156.53 | 2019-2022 | |
| Lemaitre Vascular, INC. | $105.12 | 2022 | |
| Amgen INC. | $79.21 | 2019-2020 | |
| Getinge USA Sales, LLC | $78.57 | 2020 | |
| Pfizer INC. | $48.36 | 2019-2021 | |
| Amarin Pharma, INC. | $39.72 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.46 | 2019 | |
| Abbott Laboratories | $24.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.